Premarket analyst action – healthcare
- Amneal Pharmaceuticals (NYSE:AMRX) initiated with Buy rating and $26 (77% upside) price target at Deutsche Bank (DE:DBKGn).
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) upgraded to Overweight with a $13 (68% upside) price target at Cantor Fitzgerald. Shares up 7% premarket.
- Melinta Therapeutics (NASDAQ:MLNT) upgraded to Outperform with a $15 (101% upside) price target at Robert W. Baird.
- TransEnterix (NYSEMKT:TRXC) upgraded to Buy with a $3.50 (91% upside) price target after Q1 beat. Shares up 18% premarket.
- T2 Biosystems (NASDAQ:TTOO) upgraded to Buy with a $13 (113% upside) price target at Janney. Shares up 10% premarket.
- Ironwood Pharmaceuticals (NASDAQ:IRWD) downgraded to Underweight at Morgan Stanley (NYSE:MS) on Linzess growth concerns.
- Novanta (NASDAQ:NOVT) downgraded to Neutral at Baird.
- Now read: Your Daily Pharma Scoop: IRWD Division, Jazz sNDA, Siga Adcomm
You may be interested
Bank of England’s Broadbent apologizes for ‘menopausal’ remarkadmin - May 16, 2018
LONDON - Bank of England Deputy Governor Ben Broadbent apologizes on Wednesday for describing Britain’s economy as going through a…
Garrett Camp, Uber Founder Shares His Thoughts On The Future and How To Take Advantage of Itadmin - May 15, 2018
Garrett Camp is an impressive individual with an impressive track record, he has amassed a huge fortune in his young…